Amyris, a leading synthetic biotechnology company active in the clean health and beauty markets,  announced the closing of a strategic transaction with DSM Nutritional Products, the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries.

This is the first of three anticipated transactions management described during its recent virtual investor mini-series event, held on December 15, 2020.

Under the terms of the agreement, Amyris is licensing to DSM rights to assume the supply of Farnesene to Givaudan for the production and sale of a single specialty ingredient. The transaction is valued at $50 million, with $30 million payable by December 30, 2020, $10 million payable in the first quarter of 2021, and the remainder in milestone payments thereafter.

Amyris was advised by BNP Paribas on the transaction.